Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Fineline Cube Apr 27, 2026
Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Fineline Cube Apr 27, 2026
Policy / Regulatory

China’s NHC Aims to Enhance Continuity of Medical Services with Referral System by 2030

Fineline Cube Nov 28, 2024

The National Health Commission (NHC) has released a notification aimed at enhancing the continuity of...

Company Drug

Jiangsu Kanion Pharmaceutical Secures NMPA Approvals for KYHY2302 and KYHY2303

Fineline Cube Nov 28, 2024

China-based Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced receiving separate clinical trial approvals...

Policy / Regulatory

NHSA Issues Guidelines to Suspend Direct Online Listing of In-Shortage Drugs

Fineline Cube Nov 28, 2024

The National Healthcare Security Administration (NHSA) has issued the “Guidelines for Risk Management of In-Shortage...

Company Drug

BeiGene’s Tevimbra Receives EC Approval for First-Line ESCC and G/GEJ Adenocarcinoma Treatments

Fineline Cube Nov 28, 2024

China-based biotech company BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has received a marketing...

Company Drug

Fosun Pharmaceutical’s Daxxify Receives NMPA Approval for Cervical Muscle Tone Disorders

Fineline Cube Nov 28, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National...

Company Drug

Phil Rivers Technology Secures IND Approval for PR00012 from NMPA’s CDE

Fineline Cube Nov 28, 2024

Beijing-based Phil Rivers Technology Co.,Ltd, a high-tech platform company incubated by the Institute of Computing...

Company Drug

Hansoh Pharmaceutical’s Ameile Receives NMPA Review for Fifth Indication in NSCLC Treatment

Fineline Cube Nov 28, 2024

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that its fifth indication filing...

Company Drug

China Medical System Holdings Gets NMPA Approval to Test Obesity Treatment CMS-D005

Fineline Cube Nov 28, 2024

China Medical System Holdings Ltd (CMS, HKG: 0867) has announced that it has received approval...

Company Medical Device

Genesis RMN Robotic Magnetic Navigation System Approved by China’s NMPA

Fineline Cube Nov 28, 2024

The Genesis RMN cardiac electrophysiological robot magnetic navigation system, represented in China by Shanghai Microport...

Company Drug

GSK plc Receives EC Approval for Single-Vial Menveo Vaccine for Meningococcal Disease

Fineline Cube Nov 28, 2024

GSK plc (NYSE: GSK) has announced that it has received marketing approval from the European...

Company Deals

TenNor Therapeutics Partners with Grand Life Sciences for Rifasutenizol Commercialization in China

Fineline Cube Nov 28, 2024

China-based TenNor Therapeutics has entered into an exclusive commercialization cooperation agreement with compatriot firm Grand...

Company Drug

Immunochina Pharmaceuticals’ IM19 CAR-T Therapy Accepted for Review by NMPA

Fineline Cube Nov 28, 2024

Beijing-based biotech company Immunochina Pharmaceuticals has announced that the National Medical Products Administration (NMPA) has...

Company Drug

Thederma’s TAP-1503 Cream Approved by China’s NMPA for Atopic Dermatitis Treatment

Fineline Cube Nov 28, 2024

China-based Thederma has announced that its TAP-1503 cream has been granted approval by the National...

Company Drug

Novartis’s Kisqali Approved by EC for Adjuvant Treatment of High-Risk Early Breast Cancer

Fineline Cube Nov 28, 2024

Swiss pharmaceutical company Novartis (NYSE: NVS) has announced that it has received marketing approval from...

Company

Sanofi Launches Modulus, a Pioneering Manufacturing Facility in Singapore

Fineline Cube Nov 28, 2024

Global healthcare company Sanofi (NASDAQ: SNY) has inaugurated Modulus, its state-of-the-art manufacturing facility in Singapore....

Company Drug

Chia Tai Tianqing’s Benmelstobart Combo Approved by NMPA for Endometrial Cancer Treatment

Fineline Cube Nov 27, 2024

China-based Chia Tai Tianqing has announced that the National Medical Products Administration (NMPA) has granted...

Company Drug

Sichuan Kelun-Biotech’s SKB264/MK-2870 Approved by NMPA for Triple Negative Breast Cancer

Fineline Cube Nov 27, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), a China-based biopharmaceutical company, has received market approval...

Policy / Regulatory

NHC Aims for Nationwide Inspection Result Sharing in Medical Consortia by 2030

Fineline Cube Nov 27, 2024

The National Healthcare Commission (NHC) has issued the “Guiding Opinions on Further Promoting Mutual Recognition...

Company Drug

CORXEL’s Varenicline Nasal Spray Approved by NMPA for Dry Eye Treatment

Fineline Cube Nov 27, 2024

Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, supported by RTW Investments, has received approval...

Company Deals

Arrowhead and Sarepta Seal $11.38 Billion Global Licensing Deal for Rare Disease Treatments

Fineline Cube Nov 27, 2024

US-based companies Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) and Sarepta Therapeutics (NASDAQ: SRPT) have announced a...

Posts pagination

1 … 249 250 251 … 657

Recent updates

  • Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million
  • Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China
  • Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU
  • Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104
  • Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.